Mylan inks deal with Biocon for insulin analogs but preps for more in India?
This article was originally published in Scrip
Executive Summary
Mylan, the world's third largest generics and specialty pharmaceutical company, is upping its engagement with Indian firms. It has entered into a collaboration with Biocon, India's largest biotechnology company by revenue, to develop and commercialize generic versions of three insulin analog products, amid talk that it may also be keen to snap up a formulations plant.
You may also be interested in...
Riding The Next Wave Of Biosimilars: Sandoz To Link Up With India's Biocon
Pooling resources appears key to a major new collaboration in the biosimilars space, between Sandoz and India's Biocon, to develop the next generation of biosimilar immunology and oncology products.
Riding The Next Wave Of Biosimilars: Sandoz To Link Up With India's Biocon
Pooling resources appears key to a major new collaboration in the biosimilars space, between Sandoz and India's Biocon, to develop the next generation of biosimilar immunology and oncology products.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.